Lineage Cell Therapeutics, Inc.
LCTX
$0.9853
-$0.0347-3.40%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.46% | -7.88% | 47.33% | 11.95% | -37.01% |
| Total Depreciation and Amortization | 8.61% | 7.09% | -0.70% | -18.86% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -210.63% | -125.31% | -47.23% | 2.45% | 888.02% |
| Change in Net Operating Assets | 91.12% | 18.72% | -235.02% | -19.27% | 24.29% |
| Cash from Operations | 23.01% | -9.66% | -11.80% | 10.50% | 3.92% |
| Capital Expenditure | 73.42% | -225.89% | -124.00% | -31.58% | 58.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33.33% | -25.00% | 145.75% | -- | -- |
| Cash from Investing | -27.78% | -32.23% | 144.22% | -23,039.47% | -100.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -7.69% | 7.14% | -7.69% | 0.00% |
| Issuance of Common Stock | -75.71% | 217,960.00% | -91.67% | -99.15% | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 88.44% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -286.21% | -- | 100.00% | -- | -- |
| Cash from Financing | -76.79% | 724,566.67% | -102.86% | -99.25% | 107,953.85% |
| Foreign Exchange rate Adjustments | -392.00% | -34.21% | 143.18% | -25.71% | -124.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.98% | 1,068.24% | 86.64% | -271.61% | 103.66% |